Skip to content
Screener

FormFactor FORM Cash & Equivalents

Cash & Equivalents at other companies

BK
BKBK
$9.49B+12.8%
Polaryx Therapeutics, Inc. logo
Polaryx Therapeutics, Inc.PLYX
$3.08M+1,132%
Veradermics logo
VeradermicsMANE
$168.41M+419%
Schering-Plough logo
Schering-PloughSGP
$238.9M+312%
Dollar General logo
Dollar GeneralDG
$1.35B+59.2%
Target logo
TargetTGT
$3.53B+22.4%

Other financials

Income statement

See full
Revenue$226.1M+32.0%
Gross profit$86.8M+34.5%
Operating income$16.6M+409%
Net income$20.4M+218%
EPS (diluted)$0.26+225%

Balance sheet

See full
Total debt$31.9M-14.9%
Total equity$1.1B+9.6%
Total assets$1.3B+8.6%

Cash flow

See full
Operating cash flow$45.0M+91.0%
CapEx$15.2M-18.3%
Free cash flow$29.8M+501%

Valuation

See full
Market cap$8.94B+320%
Enterprise value$8.85B+322%
P/E130.8×+82.3×
P/S10.7×+7.9×

Profitability

See full
Gross margin39.4%-1.0pp
Operating margin8.4%+2.3pp
Net margin8.1%+1.1pp
FCF margin4.4%-4.1pp

Returns & leverage

See full
Return on equity6.8%+1.0pp
Debt / equity0.0×
Current ratio4.5×+0.1×

Where this comes from

Reported directly by FormFactor in its filing.

Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents.

The source filing: FormFactor’s 10-Q, filed May 5, 2026.

Filed
May 5, 2026, 4:06 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001039399-26-000023
Line itemThree Months Ended / March 28,2026Three Months Ended / March 29,2025
Purchase of common stock through stock repurchase program(22,135)
Tax withholdings related to net share settlements of equity awards(6,751)(2,132)
Payments on term loan(281)(273)
Net cash used in financing activities(1,196)(2,964)
Effect of exchange rate changes on cash, cash equivalents and restricted cash(957)180
Net increase (decrease) in cash, cash equivalents and restricted cash19,401(63,905)
Cash, cash equivalents and restricted cash, beginning of year107,047197,206
Cash, cash equivalents and restricted cash, end of period$126,448$133,301

Item 1. Financial Statements (Unaudited):

FAQ

What is FormFactor's cash & equivalents?
FormFactor (FORM) reported cash & equivalents of $126.45M in Q1 2026.
How has FormFactor's cash & equivalents changed year-over-year?
FormFactor's cash & equivalents decreased by 5.1% year-over-year, from $133.3M to $126.45M.
What is the long-term trend for FormFactor's cash & equivalents?
Over 5 years (2020 to 2025), FormFactor's cash & equivalents has grown at a -10.9% compound annual growth rate (CAGR), from $191.1M to $107.05M.
What does cash & equivalents mean?
Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.

Ask your AI about FormFactor's cash & equivalents.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude